Entrectinib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 551 publications

Fibroblasts neurotrophin signaling sustains pathological vascular maturation in rheumatoid arthritis.

Fibroblasts neurotrophin signaling sustains pathological vascular maturation in rheumatoid arthritis.

Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026

Targeting wild type NTRK decreases brain metastases of lung cancers non-driven by NTRK fusions.

Targeting wild type NTRK decreases brain metastases of lung cancers non-driven by NTRK fusions.

Journal: bioRxiv : the preprint server for biology
Published: March 27, 2026

Discovery of a Novel Phenyl Thiophene-3-carboxamide Derivative DZX19 as an Orally TRK Inhibitor with Potent Antitumor Effects.

Discovery of a Novel Phenyl Thiophene-3-carboxamide Derivative DZX19 as an Orally TRK Inhibitor with Potent Antitumor Effects.

Journal: Journal of medicinal chemistry
Published: February 25, 2026

Case report: successful use of repotrectinib in a ROS1 fusion-positive lung adenocarcinoma patient with severe renal insufficiency and prior tyrosine kinase inhibitor treatment failure.

Case report: successful use of repotrectinib in a ROS1 fusion-positive lung adenocarcinoma patient with severe renal insufficiency and prior tyrosine kinase inhibitor treatment failure.

Journal: Anti-cancer drugs
Published: February 11, 2026

An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer.

An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer.

Journal: Expert review of anticancer therapy
Published: January 18, 2026

Development of PROTACs for targeted degradation of oncogenic TRK fusions.

Development of PROTACs for targeted degradation of oncogenic TRK fusions.

Journal: RSC chemical biology
Published: January 16, 2026

NTRK1-3 fusions in sarcomas: prevalence, significance, and clinical implications - a systematic review.

NTRK1-3 fusions in sarcomas: prevalence, significance, and clinical implications - a systematic review.

Journal: Future oncology (London, England)
Published: December 16, 2025

Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.

Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.

Journal: American journal of clinical oncology
Published: December 15, 2025

Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors

Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors

Journal: No shinkei geka. Neurological surgery
Published: December 09, 2025

Next-Generation Targeted Therapy: The Evolving Role of Taletrectinib in Fusion-Positive Malignancies.

Next-Generation Targeted Therapy: The Evolving Role of Taletrectinib in Fusion-Positive Malignancies.

Journal: Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
Published: December 09, 2025

ETV6-NTRK3 as a resistance mechanism to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: favorable response after combination of osimertinib and entrectinib: a case report and literature review.

ETV6-NTRK3 as a resistance mechanism to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: favorable response after combination of osimertinib and entrectinib: a case report and literature review.

Journal: Frontiers in pharmacology
Published: December 06, 2025

Late Onset of Entrectinib-Related ST Elevation in the Setting of Alcohol Intoxication in a Patient With Metastatic Non-small Cell Lung Cancer: A Case Report and Literature Review.

Late Onset of Entrectinib-Related ST Elevation in the Setting of Alcohol Intoxication in a Patient With Metastatic Non-small Cell Lung Cancer: A Case Report and Literature Review.

Journal: Cureus
Published: December 02, 2025
Showing 1-12 of 551

Last Updated: 04/28/2026